MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study - Ambery, Philip D.; Klammt, Sebastian; Posch, Maximillian G.; Petrone, Marcella; Pu, Wenji; Rondinone, Cristina; Jermutus, Lutz; Hirshberg, Boaz (British journal of clinical pharmacology, 2018)
Keywords: Adult; diabetes; Diabetes Mellitus, Type 2 - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; drug safety; Female; Glucagon-Like Peptide 1 - agonists; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - pharmacokinetics; Injections, Subcutaneous; Male; Original; Peptides - administration & dosage; Peptides - adverse effects; Peptides - pharmacokinetics; pharmacokinetics–pharmacodynamics; Phase 1; randomized controlled trial; Receptors, Glucagon - agonists; Young Adult; Phase 1; pharmacokinetics-pharmacodynamics; diabetes; drug safety; randomized controlled trial